[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0528767T3 - antistofderivater - Google Patents

antistofderivater

Info

Publication number
DK0528767T3
DK0528767T3 DK92810633T DK92810633T DK0528767T3 DK 0528767 T3 DK0528767 T3 DK 0528767T3 DK 92810633 T DK92810633 T DK 92810633T DK 92810633 T DK92810633 T DK 92810633T DK 0528767 T3 DK0528767 T3 DK 0528767T3
Authority
DK
Denmark
Prior art keywords
antibody derivatives
cancer
hiv
infections
aids
Prior art date
Application number
DK92810633T
Other languages
English (en)
Inventor
Hans Loibner
Mau Sung Co
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919118013A external-priority patent/GB9118013D0/en
Priority claimed from GB929204514A external-priority patent/GB9204514D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0528767T3 publication Critical patent/DK0528767T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92810633T 1991-08-21 1992-08-18 antistofderivater DK0528767T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919118013A GB9118013D0 (en) 1991-08-21 1991-08-21 Monoclonal antibodies and their use
GB929204514A GB9204514D0 (en) 1992-03-02 1992-03-02 Monoclonal antibodies and their use

Publications (1)

Publication Number Publication Date
DK0528767T3 true DK0528767T3 (da) 2000-04-17

Family

ID=26299429

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92810633T DK0528767T3 (da) 1991-08-21 1992-08-18 antistofderivater

Country Status (10)

Country Link
US (1) US5562903A (da)
EP (1) EP0528767B1 (da)
JP (1) JP3474592B2 (da)
AT (1) ATE188708T1 (da)
CA (1) CA2076432C (da)
DE (1) DE69230545T2 (da)
DK (1) DK0528767T3 (da)
ES (1) ES2145004T3 (da)
GR (1) GR3032944T3 (da)
PT (1) PT528767E (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324584T2 (de) * 1992-05-22 1999-09-23 Novartis Ag, Basel Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
WO2000047625A2 (en) * 1999-02-12 2000-08-17 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
AT500648B1 (de) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
US7780992B2 (en) * 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7759464B2 (en) 2004-07-14 2010-07-20 Greenovation Biotech Gmbh N-glycosylated antibody
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2006082406A2 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
MX2008015049A (es) * 2006-06-07 2009-02-16 Bioalliance Cv Anticuerpos que reconocen un carbohidrato que contiene epitope en cd-43 y antigeno carcinoembrionico expresados en celulas cancerigenas y metodos que usan los mismos.
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
CN101675074B (zh) * 2006-12-20 2016-02-24 Mmr全球公司 抗体及其制备和使用方法
WO2009018122A2 (en) * 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
DK2245063T3 (da) 2007-12-18 2015-12-07 Bioalliance Cv Antistoffer, der genkender en kulhydratholdig epitop på cd-43 og cea eksprimeret på cancerceller, og fremgangsmåder, hvorved disse anvendes
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US8791243B2 (en) * 2007-12-28 2014-07-29 Onclave Therapeutics Limited Treatment and prophylaxis of amyloidosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
JP5818688B2 (ja) * 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 核酸増幅反応の効率を改善するための方法および組成物
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
ES2937174T3 (es) * 2010-05-14 2023-03-24 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD47
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
JP2012067106A (ja) * 2011-10-14 2012-04-05 Greenovation Biotech Gmbh グリコシル化抗体
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CN110381988A (zh) 2016-06-15 2019-10-25 诺华股份有限公司 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
CN109266656B (zh) * 2018-10-10 2021-02-19 江苏集萃药康生物科技股份有限公司 一种PD1人源化BALB/c小鼠模型的构建方法及其应用
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA1340456C (en) * 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen

Also Published As

Publication number Publication date
PT528767E (pt) 2000-06-30
CA2076432A1 (en) 1993-02-22
EP0528767B1 (en) 2000-01-12
DE69230545T2 (de) 2000-07-06
JPH05336989A (ja) 1993-12-21
CA2076432C (en) 2003-10-21
EP0528767A1 (en) 1993-02-24
ES2145004T3 (es) 2000-07-01
ATE188708T1 (de) 2000-01-15
US5562903A (en) 1996-10-08
DE69230545D1 (de) 2000-02-17
JP3474592B2 (ja) 2003-12-08
GR3032944T3 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
DK0528767T3 (da) antistofderivater
ATE123652T1 (de) Antigene.
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
IT9068053A0 (it) Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego
NO862641D0 (no) Monoklonalt antistoff for et antigen tilknyttet human karsinoma tumor.
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
ATE171207T1 (de) Monoklonaler antikörper
DK0552296T3 (da) Monoklonale antistoffer fra mus
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
EP0198086A4 (en) MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY.
NO870476D0 (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
DE69119591D1 (de) Das von mca-28a32 erkannte antigen
ZA884777B (en) Antigen recognized by mca 16 88
FI945485A (fi) Monoklonaaliset vasta-aineet ja niiden käyttö
DE69025629D1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
EP0334076A3 (en) Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
NO952506L (no) Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker